Escherichia coli O157 fails to induce a long-lasting lipopolysaccharide-specific, measurable humoral immune response in children with hemolytic-uremic syndrome

Journal of Infectious Diseases

Volumn 186, Issue 4, 2002, Pages 566-569

  Ludwig, Kerstin ^a   Bitzan, Martin ^c   Bobrowski, Christoph ^b   Müller Wiefel, Dirk E ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; CHILD; CONTROLLED STUDY; DIARRHEA; ENTEROPATHY; ENZYME IMMUNOASSAY; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

EID: 0037103635     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/341781     Document Type: Article

References (15)

1. Infection by verocytotoxin-producing Escherichia coli
2. The epidemiology of infectious caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome
3. Shiga toxin-producing Escherichia coli: Yesterday, today, and tomorrow
4. Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections
5. Escherichia coli O157:H7 and the hemolytic-uremic syndrome: Importance of early cultures in establishing the etiology
6. Serum antibodies to Escherichia coli serotype O157:H7 in patients with hemolytic-uremic syndrome
7. The role of Escherichia coli O157 infections in the classical (enteropathic) haemolytic uraemic syndrome: Results of a Central European, multicentre study
8. Humoral immune responses to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjects
9. Outbreak of Escherichia coli O157:H7 infection in a large family
10. Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents
11. The United States national prospective hemolytic-uremic syndrome study: Microbiologic, serologic, clinical, and epidemiologic findings
12. Immune response to non-O157 Vero toxin-producing Escherichia coli in patients with hemolytic-uremic syndrome
13. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israel volunteers
14. Recurrent hemolytic-uremic syndrome secondary to Escherichia coli O157:H7 infection
15. Investigational vaccine for Escherichia coli O157: Phase 1 study of O157 O-specific polysaccharide - Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults